

Resource Summary Report

Generated by ASWG on Aug 9, 2026

APC anti-human/mouse Granzyme B Recombinant

RRID:AB_2687028

Type: Antibody

Proper Citation

BioLegend Cat# 372204, RRID:AB_2687028

Antibody Information

URL: http://antibodyregistry.org/AB_2687028

Proper Citation: BioLegend Cat# 372204, RRID:AB_2687028

Target Antigen: Granzyme B

Host Organism: mouse

Clonality: recombinant monoclonal

Comments: Applications: ICFC

Antibody Name: APC anti-human/mouse Granzyme B Recombinant

Description: This recombinant monoclonal targets Granzyme B

Target Organism: Human, Mouse

Clone ID: Clone QA16A02

Antibody ID: AB_2687028

Vendor: BioLegend

Catalog Number: 372204

Alternative Catalog Numbers: 372203

Record Creation Time: 20250820T070455+0000

Record Last Update: 20250821T013328+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-human/mouse Granzyme B Recombinant.

No alerts have been found for APC anti-human/mouse Granzyme B Recombinant.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 42 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Wang X, et al. (2026) Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases. *Cancer cell*, 44(3), 658.

Yu X, et al. (2026) Bacterial vesicles from intratumoral *L. salivarius* enhance PD-1 blockade via FPR1-mediated macrophage polarization in gastric cancer. *Cell reports. Medicine*, 7(2), 102621.

Herbrich S, et al. (2026) TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors. *Cancer cell*, 44(1), 187.

Du Y, et al. (2026) AARS1-mediated lactylation of STAT1 drives immune evasion. *Cell reports*, 45(3), 117094.

Li YR, et al. (2026) Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against solid tumors. *Signal transduction and targeted therapy*, 11(1).

Zhou YD, et al. (2026) Tissue-specific tolerance mechanisms and lymph node co-drainage shape T cell immunity in the upper digestive system and pancreatic cancer progression. *Cell reports*, 45(5), 117324.

Xie S, et al. (2026) Effector differentiation by stem-like intraepithelial ?? T cells is required for host defense against infection. *Immunity*, 59(3), 577.

Liu Y, et al. (2026) Immunogenic tumor cell death and T-cell-derived IFN-? elicit tumoricidal macrophages to potentiate OX40 immunotherapy. *Cell reports. Medicine*, 7(4), 102699.

Li YR, et al. (2025) Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture. *Nature protocols*, 20(5), 1352.

Li B, et al. (2025) Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis. *Cell*, 188(14), 3823.

Li YR, et al. (2025) Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. *Med (New York, N.Y.)*, 100804.

Zhang M, et al. (2025) Microbiota-derived urocanic acid triggered by tyrosine kinase inhibitors potentiates cancer immunotherapy efficacy. *Cell host & microbe*, 33(6), 915.

Lv J, et al. (2025) Mechanical signaling via $\alpha 2$ integrin decouples T cell proliferation and differentiation for generating stem cell-like CAR T cells. *Immunity*, 58(9), 2289.

Li YR, et al. (2025) Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells. *Cell reports. Medicine*, 6(9), 102321.

Wang Z, et al. (2025) Relationship between iron deficiency and severity of tuberculosis: Influence on T cell subsets. *iScience*, 28(2), 111709.

Zhou YD, et al. (2025) T cell fate is dictated by different antigen presenting cells in response to dietary versus gut epithelial self-antigen. *bioRxiv : the preprint server for biology*.

Xie M, et al. (2025) Tumor-resident probiotic *Clostridium butyricum* improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression. *Cancer cell*.

Li T, et al. (2025) Non-canonical PRC1.1 licenses transcriptional response to enable Treg plasticity in immune adaptation. *Molecular cell*, 85(13), 2517.

Wu CY, et al. (2025) Glucose restriction shapes pre-metastatic innate immune landscapes in the lung through exosomal TRAIL. *Cell*.

Niekamp P, et al. (2025) The Nuclear Receptor NR1B1/RAR γ Arrests the Differentiation of Anti-Tumor Effector Cytotoxic T Cells. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(17), e2410241.